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Purpose: To characterize various properties of a physiologically-relevant artificial tear solution (ATS) containing a range
of tear film components within a complex salt solution, and to measure contact lens parameters and lipid deposition of a
variety of contact lens materials after incubation in this ATS.
Methods: A complex ATS was developed that contains a range of salts, proteins, lipids, mucin, and other tear film
constituents in tear-film relevant concentrations. This ATS was tested to confirm that its pH, osmolality, surface tension,
and homogeneity are similar to human tears and remain so throughout the material incubation process, for up to 4 weeks.
To confirm that silicone hydrogel and conventional hydrogel contact lens materials do not alter in physical characteristics
beyond what is allowed by the International Organization for Standardization (ISO) 18369–2. The diameter, center
thickness, and calculated base curve were measured for five different lens materials directly out of the blister pack, after
a rinse in saline and then following a two week incubation in the modified ATS. To test the ATS and the effect of its
composition on lipid deposition, two lens materials were incubated in the ATS and a modified version for several time
points.  Both  ATS  solutions  contained  trace  amounts  of  carbon-14  cholesterol  and  phosphatidylcholine,  such  that
deposition of these specific lipids could be quantified using standard methods.
Results: This ATS is a complex mixture that remains stable at physiologically relevant pH (7.3–7.6), osmolality (304–
306 mmol/kg), surface tension (40–46 dynes/cm) and homogeneity over an incubation period of three weeks or more.
The physical parameters of the lenses tested showed no changes beyond that allowed by the ISO guidelines. Incubations
with the ATS found that balafilcon A lenses deposit significantly more cholesterol and phosphatidylcholine than omafilcon
A lenses (p<0.05) and that removing lactoferrin and immunoglobulin G from the ATS can significantly decrease the mass
of lipid deposited.
Conclusions: This paper describes a novel complex artificial tear solution specially designed for in-vial incubation of
contact lens materials. This solution was stable and did not adversely affect the physical parameters of the soft contact
lenses incubated within it and showed that lipid deposition was responsive to changes in ATS composition.
In vitro biomaterial models have been used extensively
to analyze surface interactions that occur with an implanted
medical device and their surroundings [1-5]. Contact lenses
are similar to an implant in that they are a biomaterial that is
exposed to a very complex biologic environment, in some
cases  more  complex  than  permanently  implanted
biomaterials, such as a hip or knee replacement. Unlike these
biomaterials, contact lenses are exposed to a continuously
changing  tear  film  composition  and  structure,  induced  by
continuous blinking and drying of the lens surface, changes
in  environmental  surroundings,  systemic  diseases,
medications, alcohol consumption and diet [6-9].
The composition of the human tear film is complex and
contains several layers, including a glycocalyx-like mucin
layer covering the corneal epithelium, an aqueous layer rich
in proteins, salts and electrolytes, and a lipid layer divided into
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both a polar and non-polar lipid component [10-12]. Although
this layered tear film model is still favored, it is now believed
that this structure is not as compartmentalized as previously
thought and that the components from each layer can be found
throughout  the  entire  tear  film  [13-17].  Soft  contact  lens
materials, once inserted into the eye, lie in the middle of this
tear film structure and are known to readily adsorb many
different tear film components, including lipids, proteins, and
mucins [18-27].
Building an in vitro model to examine deposition of tear
film components onto contact lens materials would allow for
systematic and structured analysis of tear film interactions.
These models could then be used to analyze various lens
materials and their affinity for different tear film components,
the conformation of proteins on contact lens materials, the
exploration  of  tear  film  component  interactions  and
competition, and the effectiveness of contact lens cleaning
solutions to remove such deposits. These types of experiments
would be difficult, if not impossible, to conduct in a controlled
manner using in vivo or ex vivo studies. Therefore, in vitro
models  examining  these  interactions  and  processes  can
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3392provide pertinent information to further our understanding of
the ever growing field of contact lens material science.
In vitro models have many benefits over in-eye clinical
studies. They allow for analysis of specific variables without
the use of human or animal testing, the variables are easily
and tightly controlled in laboratory settings, many different
analysis techniques can be used that otherwise would not be
available using in vivo or ex vivo based studies, allow for the
examination of both simple and complex models, and lastly
in vitro studies tend to require less financial support and time
to conduct, since participant remuneration and ethics approval
are not required.
Although  in  vitro  models  can  never  fully  mimic  the
complex  nature  of  human  contact  lens  wear,  they  can  be
designed to be physiologically relevant and help understand
the basic tear film interactions that occur. Many early in vitro
contact lens deposition models involved incubating contact
lens materials in a simple saline solution with one tear film
component, such as a single protein or lipid [18,24,28-31].
This model is very simplistic and is not indicative of what is
found in the human tear film. It is clear that there is a relative
dearth  of  information  on  contact  lens  in  vitro  models,
especially for lipid deposition.
More recently, researchers have started to increase the
complexity of the artificial tear solutions used to mimic the
tear film. Mirejovsky et al. [32] was the first to report on the
use of a complex artificial tear film that contained a range of
salts, proteins, and lipids. Artificial tear solutions used in in
vitro  studies  must  contain  physiologically  relevant
components,  maintain  physiologically  relevant  solution
properties and must not change the contact lens parameters
during incubation, as alterations in these parameters can cause
changes  in  the  contact  lens  dimensions  themselves.  The
contact lenses may swell/shrink, thicken/thin, or experience a
change in their base curve if an inappropriate solution is used.
These  lens  parameter  changes  could  alter  the  deposition
pattern and lens interactions with tear film components. If in
vitro contact lens deposition models are to mimic human
contact lens wear, then the artificial tear solutions used must
be more complex than a single component system. Recent
work from our laboratory has shown that an in vitro incubation
solution consisting of a mixture of lipids, proteins, mucins and
buffers is significantly different to that obtained in an in vitro
model which uses single lipids alone [33]. In this study, we
wanted to explore how sensitive the lipid deposition was to
smaller  changes  in  solution,  such  as  adding  or  removing
individual components.
Our  laboratory  has  characterized  a  complex
physiologically  relevant  artificial  tear  solution  (ATS)
designed for in vitro vial-enclosed incubation experiments.
This solution has been tested to determine if the solution and
contact lens parameters remain stable throughout contact lens
incubation. Although this solution does not contain all of the
individual human tear film components, it does contain a
broad representation of the most abundant lipids, proteins,
mucin, salts, and inorganics that are present.
METHODS
The ATS composition: ATS preparation required four main
steps. These included preparation of the complex salt solution,
lipid stock solution, adding lipids to the salt solution, and
addition of the proteins and mucin to complete the solution.
The complex salt solution—The first step in making an
ATS was the preparation of a complex salt solution (CSS).
The composition of the CSS, which is used as the base of the
ATS,  is  shown  in  Table  1.  These  specific  salts  and  their
relative  concentrations  are  based  on  literature  values  [32,
34-36]. All CSS components were ACS grade and purchased
from Sigma (Oakville, ON). The individual components were
measured on an analytical balance and sequentially added to
the desired volume of MilliQ water in the order that they are
listed in table. Once all of the components had been added,
ProClin  300  (Sigma,  Oakville,  ON),  a  preservative  and
antimicrobial agent, was added to the system. The use of
ProClin 300 allows for incubation at 37 °C for prolonged
periods of time with no fear of microbial contamination. After
all the ingredients were added, the pH was approximately 7.15
and the osmolality was 305 mmol/kg. When the CSS was left
at room temperature for three or more days it equilibrated
naturally to the desired pH of 7.4, which is the typical pH of
the human tear film [37]. However, if the solution was to be
used immediately then purging with nitrogen gas equilibrated
the solution to the desired pH much faster.
Concentrated lipid stock solution—The next step in the
ATS preparation was to make a concentrated lipid stock. Here,
a 2,000× concentrated lipid stock solution (LSS) was made to
help facilitate dissolving the pure lipids into the CSS. Lipids,
especially  non-polar  lipids,  do  not  naturally  dissolve  into
aqueous solutions, so dissolving them first into a solution of
1 hexane: 1 ether and then adding an aliquot of the hexane/
ether LSS to the CSS helps facilitate the incorporation of
lipids. To make a LSS, pure lipids were warmed up to room
temperature  and  weighed  out  using  an  analytical  balance
(solid lipids) or pipetted using a positive displacement pipette
(liquid lipids). The concentrated LSS was placed in an amber
vial,  sealed  with  Parafilm®  (VWR,  Mississauga,  ON),
wrapped in foil and stored at −20 °C until required. Table 2
shows the lipids used in the ATS, their characteristics, the lipid
stock concentration and final ATS concentration used for each
lipid. All pure lipids were purchased through Sigma (Oakville,
ON). The lipids used in this ATS were chosen specifically so
that a broad range of human tear film lipids were represented
and their concentrations were chosen based on human tear
film concentrations, artificial tear solution literature values,
and lipid solubility in aqueous solutions [28,32,38-40].
Lipid artificial tear solution—The next step in making
an ATS was to make the lipid artificial tear solution (LTS).
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3393This was accomplished by removing the LSS from the freezer
and allowing it to warm up to room temperature in a dry dark
place. The desired volume of room temperature CSS was
placed into a glass septum jar and the required volume of LSS
was added to the CSS. The cap was screwed onto the septum
jar and the whole jar was placed into an ultra-sonic bath that
was warmed to 37 °C. Two syringes were pierced through the
septum, one large blunt syringe was placed into the solution
and one smaller syringe was left sitting in the air space of the
septum jar. The large syringe was connected to a nitrogen tank
and the small syringe remained open to air to act as a vent.
The LTS was sonicated at 90 W and purged with nitrogen gas
at a pressure of 3 psi until the LSS was fully incorporated into
the CSS and the odour of hexane:ether had dissipated. The
LTS was now complete.
Incorporation  of  proteins  and  mucin  to  complete
preparation of the ATS—The last step in preparing the ATS
was the addition of proteins and mucin. The specific proteins
and mucin used and their concentrations in the final ATS are
outlined in Table 3 and are based on literature values of the
human tear film, literature ATS concentrations, and based on
the cost of the component, as in the case of lactoferrin and IgG
[32,41-48].  All  proteins  and  mucin  were  purchased  from
Sigma. Bovine and hen-egg proteins were chosen for use in
this ATS due to their cost and their similarities to human
proteins in molecular weight, pI, amino acid chain length, and
number of charged residues. The proteins and mucin were
weighed out on an analytical balance and added to the LTS
while stirring. When all components were incorporated fully,
the complete ATS was sonicated at 37 °C for a maximum of
5 min, to prevent destruction of the proteins [49].
Solution properties:
pH  and  osmolality—To  test  the  consistency  of  the
ATS’s pH and osmolality during in vitro incubations, a 28 day
TABLE 1. ARTIFICIAL TEAR SOLUTION COMPLEX SALT SOLUTION COMPONENTS [35-38].
Salt component Molecular formula mM
Sodium chloride NaCl 90.0
Potassium chloride KCl 16.0
Sodium citrate Na3C6H5O7 1.5
Glucose C6H12O6 0.2
Urea (NH2)2CO 1.2
Calcium chloride CaCl2 0.5
Sodium carbonate Na2CO3 12.0
Potassium hydrogen carbonate KHCO3 3.0
Sodium phosphate dibasic Na2HPO4 24.0
Hydrochloric acid (10 molar) HCl 26.0
ProClin 300 (Supelco 48912-U)   0.2 µl/ 1l
MilliQ Water    
TABLE 2. MOLECULAR AND EXPERIMENTAL DETAILS OF THE SPECIFIC LIPIDS USED FOR ALL LIPID INCUBATION SOLUTIONS [28,35,40-42].






Lipid type Triglyceride Sterol Fatty acid Fatty ester Cholesteryl ester Phospholipid
Formula C57H104O6 C27H46O C18H34O2 C19H36O2 C45H78O2 C42H82NO8P
Molecular Weight (g/mol) 885.5 386.7 282.5 296.5 651 760.1
Lipid Stock Concentration (mg/ml) 32.0 3.6 3.6 24.0 48.0 1.0
Final ATS Concentration (mg/ml) 0.016 0.0018 0.0018 0.012 0.024 0.0005






Bovine albumin 66.4 0.20 A7888
Hen egg lysozyme 14.3 1.90 L6876
Bovine submaxillary mucin 3×105 to 4×107 0.15 M3895
Bovine colostrum lactoferrin 83.1 1.80 L4765
Bovine immunoglobulin G 161 0.02 I5506
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3394study was performed. Clear borosilicate glass 6 mL vials were
half filled with freshly made ATS with a starting pH of 7.35
and an osmolality of 305 mmol/kg. Vials were closed with
PTFE-sealed screw caps, further sealed with Parafilm® and
incubated at 37 °C for six different time points including: 1,
3, 7, 14, 21, and 28 days in triplicate. On the specific days, the
vials  were  opened  and  the  pH  was  measured  using  the
SympHony SB20 pH meter (VWR, Mississauga, ON) and the
osmolality was measured using the Wescor “Vapro” Vapor
Pressure  Osmometer  5520  (Discovery  Diagnostics,
Claremont, ON).
Surface tension and homogeneity of ATS—To test the
surface tension and liposome homogeneity of the solution a
3.5 week study was conducted. Fresh ATS was made and
tested for its surface tension and homogeneity and then the
ATS was incubated for 3.5 weeks at 37 °C and tested again
for the two parameters. Surface tension was measured using
the Wilhelmy balance (CAHN Instruments, Madison, WI)
using a platinum ring and the homogeneity of the solution was
tested by staining liposomes in the ATS with Nile Red. To
stain with Nile Red, the Nile Red was dissolved in acetone at
1 mg/ml, then 1 µl of the Nile Red solution was added to 100 µl
of the test solution in a micro-centrifuge tube and shaken so
the two components were well mixed [32]. Then 20 µl of the
Nile  Red  test  solution  was  then  pipetted  onto  a  slide
(prewashed with methanol), and a coverslip was placed on top.
The sample was then examined and photographed on the
microscope at 10× and 40× magnifications using a green light
filter. Samples of the complex salt solution and artificial tear
solution were analyzed at several points in the preparation
process and compared with the solution after 3.5 weeks of
incubation. The distribution and diameter of the liposomes
was analyzed for each sample.
Lens parameters: Five contact lens materials were tested in
triplicate: Acuvue® 2 (etafilcon A; Vistakon, Jacksonville,
FL), Proclear® (omafilcon A; CooperVision, Pleasanton, CA),
Acuvue®  OASYS™  (senofilcon  A;  Vistakon),  Biofinity®
(comfilcon A; CooperVision), PureVision™ (balafilcon A;
Bausch & Lomb, Rochester, NY). The material characteristics
of all contact lens materials can be found in Table 4 and Table
5. All lens materials tested had a spherical power of −3.00
diopters  (D)  and  had  an  approximate  base  curve  of
8.6±0.2 mm. The individual lenses were measured on three
separate  occasions:  out  of  the  blister  pack,  after  40  h  of
soaking in CSS, and after a 2 weeks incubation at 37 °C in the
ATS  previously  described.  The  center  thickness  was
measured using a Rehder Development Co. E.T.-1 (Castro
Valley, CA) and the diameter and sagittal height (Sag) of each
lens  was  measured  using  the  Optimec  Soft  Contact  Lens
Analyzer (Malvern, UK). The base curve was then calculated
from the diameter and sagittal height. The data were analyzed
using  Statistica  9  using  paired  t-tests.  The  contact  lens
parameter  measurements  were  taken  so  that  comparisons
could be made between the three parameters tested and was
not meant to assess the contact lens parameter variability from
their specified package dimensions.
Lipid deposition: As the last step of the ATS characterization
process, the ATS was examined for its lipid deposition using
a simple radioactive experiment previously developed by our
laboratory. In this experiment, omafilcon A and balafilcon A
lens materials were incubated in two different ATS solutions
for three different time periods, as outlined in Figure 1. The
first  ATS  solution  composition  was  identical  to  the  ATS
described above (+LF/IgG) and the second ATS solution was
a  slightly  simpler  version  with  lactoferrin  (LF)  and
immunoglobulin G (IgG) removed (- LF/IgG). To facilitate
sensitive  quantification  of  lipid  deposition,  both  ATS
solutions were prepared by adding a small aliquot of one of
two  radiolabelled  lipids  (Table  6);  14C-cholesterol  or  14C-
phosphatidylcholine. Lenses (n=3) were then incubated in
each solution for 3, 7, and 20 days.
At the end of the incubation period, each lens was rinsed
twice in saline and blotted on lens paper. The lenses were then
placed in 20 ml glass scintillation vials with 2 ml of 2:1
TABLE 4. CONVENTIONAL HYDROGEL CONTACT LENS MATERIAL CHARACTERISTICS.
Material type Conventional hydrogel
USAN Etafilcon A Omafilcon A
Proprietary name Acuvue®2 Proclear®
Manufacturer Johnson & Johnson CooperVision
Power (D) −3.00 −3.00
Base Curve (mm) 8.7 8.6
Diameter (mm) 14.0 14.2
Monomers HEMA, MA HEMA, PhC
Surface Modification None None
Oxygen Transmissibility (×10−9) 31.0 52.3
Water Content 58% 62%
FDA class Group IV Group II
        USAN:  United  States  adopted  name;  HEMA  (poly-2-hydroxyethyl  methacrylate);  MA  (methacrylic  acid);  PhC
        (phosphorylcholine).
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3395chloroform:methanol extraction solution and were incubated
for three hours each at 37 °C while shaking on an orbital
shaker. Each lens was extracted in this way on two separate
occasions and both extracts were pooled together in the same
vial.
The extract vials were dried completely using nitrogen
evaporation at 37 °C. All samples were re-suspended in 1 ml
of chloroform, sonicated for one min, and 10 ml of Ultima
Gold  F  scintillation  cocktail  (Perkin-Elmer,  Woodbridge,
ON)  was  added.  The  vials  were  submitted  for  liquid
scintillation  beta  counting.  Standard  lipid  samples  were
prepared and all data were analyzed and quantified using
standard calibration curves.
RESULTS
pH and osmolality: When examining the stability of pH and
osmolality of the ATS it was found that pH ranged from 7.35
to 7.49 and osmolality ranged from 305.0 to 303.7 mmol/kg,
over the 28 days of incubation.
Surface tension and homogeneity of ATS: After the complex
salt  solution  and  ATS  preparation  was  complete,  several
aliquots of each solution were stained with Nile Red examined
microscopically at 200×-400× and photographed. Following
a three week in-vial incubation, ATS aliquots were once again
stained and photographed. Following staining with Nile Red,
the  CSS  samples  had  no  visible  liposomes  present  in  its
solution, as expected. However, both ATS samples, freshly
made  and  post  incubation  solutions,  showed  similar
distribution and sizes of liposomes stained by the Nile Red.
The liposomes present in both ATS solutions ranged in size
from 6 to 20 µm, with average sizes around 12 µm. Therefore,
no  discernible  differences  were  found  in  fresh  versus
incubated ATS solutions in terms of its homogeneity.
The surface tension of the freshly prepared ATS was
51.5±0.38 dynes/cm and following the 25 days of incubation
the surface tension fell to 45.05±1.25 dynes/cm. This is an
average change of −6.46±1.30 dynes/cm.
Lens parameters: The center thickness of each lens material
measured out of blister pack, following a saline soak, and after
ATS incubation at 37 °C for two weeks can be graphically
seen in Figure 2. One statistically significant difference was
seen when analyzing the difference between the blister pack
and  post-incubation  conditions.  Omafilcon  A  lenses
experienced  a  1.0%  average  increase  in  center  thickness
following two week incubation in ATS. These changes in
center  thickness  would  not  correlate  to  any  significant
clinically relevant changes in vivo.
The average contact lens diameter results measured out
of blister pack, following a CSS soak, and following a two
week incubation in ATS can been seen in Figure 3. Only
etafilcon A had a statistically significant change in diameter
following incubation in ATS, where the average diameter
decreased  by  0.81%.  These  changes  in  diameter  are  not
considered to correlate to any clinically significant changes in
vivo.
TABLE 5. SILICONE HYDROGEL CONTACT LENS MATERIAL CHARACTERISTICS.
Material Type Silicone Hydrogel
USAN Senofilcon A Comfilcon A Balafilcon A
Proprietary name Acuvue® OASYS™ Biofinity® PureVision™
Manufacturer Johnson & Johnson CooperVision Bausch & Lomb
Power (D) −3.00 −3.00 −3.00
Base curve (mm) 8.4 8.6 8.6
Diameter (mm) 14.0 14.0 14.0
Centre thickness (mm) −3.00D 0.07 0.08 0.09
Monomers mPDMS, DMA, HEMA, siloxane
macromer, EGDMA, PVP
M3U, FM0411M, HOB, IBM,
NVP, TAIC, VMA
NVP, TPVC, NVA, PBVC
Surface modification PVP as an internal wetting agent None Plasma oxidation
Oxygen transmissibility (×10−9) 147 160 110
Modulus (MPa) 0.7 0.75 1.1
Water content 38% 48% 36%
FDA class Group I Group I Group III
        USAN: United States adopted name; DMA (N,N-dimethylacrylamide); EGDMA (ethyleneglycol dimethacrylate); FM0411M
        (2-ethyl  [2-[(2-methylprop-2-enoyl)oxy]ethyl]carbamate);  HEMA  (poly-2-hydroxyethyl  methacrylate);  HOB  ((2RS)-2-
        hydroxybutyl  2-methylprop-2-enoate);  IBM  (Isobornyl  methacrylate);  M3U  (α-[[3-(2-[[2-(methacryloyloxy)ethyl]
        carbamoyloxy]ethoxy)propyl]dimethylsilyl]-ω-[3-(2-[[2-(methacryloyloxy)ethyl]
        carbamoyloxy]ethoxy)propyl]poly([oxy[(methyl)  [3-[ω-methylpoly(oxyethylene)oxy]propyl]silylene]  /[oxy[(methyl)(3,3,3-
        trifluoropropyl)]silylene]/oxy  (dimethylsilylene)]));  mPDMS  (monofunctional  polydimethylsiloxane);  NVA  N-vinyl
        aminobutyric acid; NVP (N-vinyl pyrrolidone); PBVC (poly[dimethysiloxy] di [silylbutanol] bis[vinyl carbamate]); PVP
        (poly(vinylpyrrolidone));  TAIC  (1,3,5-triprop-2-enyl-1,3,5-triazine-2,4,6(1H,3H,5H)-trione);  TPVC  (tris-
        (trimethylsiloxysilyl) propylvinyl carbamate); VMA (N-Vinyl-N-methylacetamide).
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after  each  lens  treatment  are  displayed  in  Figure  4.  No
statistically significant differences were seen when comparing
the blister pack measurements to the post-incubation in ATS
measurements for any lens material.
Contact lens lipid deposition: The results of the radioactive
cholesterol (C) and phosphatidylcholine (PC) kinetic uptake
with and without the presence of lactoferrin and IgG can be
seen in Figure 5 and Figure 6. As seen in the figures below,
the silicone hydrogel lens material deposited more than the
conventional hydrogel lens and that more cholesterol was
deposited than phosphatidylcholine. The lipid uptake for all
lens  materials,  especially  the  silicone  hydrogels,  was
continuous throughout the 20 day period, with no plateau. The
presence of lactoferrin and IgG in the ATS correlated with a
statistically  significant  increase  in  cholesterol  and  PC
deposition for balafilcon A at every time point (p≤0.001).
Cholesterol deposition on omafilcon A in the presence of LF/
IgG was greater than without, however the trend was not
statistically significant for any time point (p>0.05). However,
PC  deposition  on  omafilcon  A  did  show  statistically
significant increases in the presence of LF/IgG for every time
point (p≤0.008). Overall, there were statistically significant
differences in the entire repeated measures ANOVA model,
including all the variables and variable interactions for each
lipid tested, as seen in Table 7 and Table 8.
DISCUSSION
In the creation of an in vitro model designed to analyze the
dynamics of tear film interactions on a contact lens surface,
the development of an appropriate artificial tear solution that
is both physiologically relevant and stable is imperative. A
handful  of  papers  has  been  published  using  in  vitro
experimental  models  to  examine  contact  lenses,  their
deposition and their tear film interactions. Many of these
papers have used very simple in vitro solution models with
single components for investigation, such as a single lipid or
protein.  These  individual  component  model  systems  have
been regularly used for the past 25 years and are continually
being  used.  In  the  mid-1980s,  Castillo  et  al.  [50]  used
Figure 1. Lipid deposition study outline
using the artificial tear solution (ATS)
and two radiolabeled lipids.




Cholesterol [C] 4-14C 386.6 Perkin-Elmer
L-α-DiPalmitoyl-Phosphatidylcholine [PC] DiPalmitoyl-1-14C 734.0 Perkin-Elmer
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3397lysozyme  incubation  solutions  dissolved  in  a  phosphate
buffered saline (PBS) to examine conformational changes that
occur  on  PHEMA  materials  fabricated  using  different
methods via ATR-FTIR. Garrett et al. [24] and several studies
from Jones et al. [18,29,30] used lysozyme or lactoferrin-only
solutions  in  PBS  for  radiochemical  studies  examining
lysozyme or lactoferrin adsorption and conformation onto
various contact lens materials. Similar to proteins, there are
several papers using single lipid in vitro systems, including
Carney and colleagues work in 2008, where they examined
kinetic uptake of lipid onto various contact lens materials
using  fluorescently  labeled  cholesterol  and
phosphatidylethanolamine  solutions  independently  [28].
Most recently, Pucker et al. [31] published a similar paper
examining  the  uptake  of  cholesterol  oleate  and
phosphatidylcholine  separately  in  an  undisclosed  buffer
solution. In most of these publications, a PBS solution with a
single lipid or protein is used; however in many of the papers
there is no information about the specific composition or
concentrations of the PBS itself. Since there is no standardized
composition  of  PBS,  many  of  these  papers  are  lacking
important information regarding the ATS used.
There are several experimental papers where moderately
complex in vitro artificial tear solutions were used. These
solutions are mixtures of proteins or lipids dissolved into a
saline base. Castillo et al. [51] and Bohnert et al. [52] both
used an ATS which contained a mixture of several proteins
dissolved into a saline solution to examine protein adsorption
and conformation onto contact lens materials. Ho and Hlady
examined lipid deposition using a mixture of several lipids
dissolved into a more complex mixture of salts [53]. In each
of these three examples, lipids and protein components were
Figure 2. Average center thickness of all
studied  lens  materials  as  measured
directly from the blister pack, after a
saline  soak,  and  following  14  days
incubation in ATS.
Figure 3. Average contact lens diameter
of  all  studied  materials  as  measured
directly from the blister pack, after a
saline  soak,  and  following  14  days
incubation in ATS.
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3398not  mixed  together  within  the  ATS  and  there  was  no
incorporation of mucin.
Recent work from our laboratory [33] and past work from
Bontempo and Rapp [23,54] have found a dramatic difference
in  the  amount  of  lipids  and  proteins  deposited  onto
conventional  and  silicone  hydrogel  contact  lens  materials
from an ATS of different complexities. Single component
systems, moderately complex systems (no mixing of lipids
and proteins together) and complex multiple lipid and protein
systems  have  different  deposition  behaviors.  Although
simpler systems can be useful for particular experimental
models, they are unsuitable to mimic human contact lens wear
deposition  and  tear  film  interactions,  due  to  their  lack  of
complexity.
Figure  4.  Average  contact  lens  base
curve  of  all  studied  materials  as
measured directly from the blister pack,
after  a  saline  soak,  and  following  14
days incubation in ATS.
Figure  5.  Cholesterol  deposition  with
and  without  lactoferrin  and
immunoglobulin G for omafilcon A and
balafilcon  A.  -LF/IgG=no  lactoferrin
and  immunoglobulin  G  in  the  ATS.
+LF/IgG=lactoferrin  and
immunoglobulin G were present in the
ATS.
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3399Papers have been published introducing more complex in
vitro artificial tear solutions. The first of these papers was by
Mirejovsky et al. [32] in 1991, where lipids, proteins, mucin,
and a variety of salts were all incorporated to form a complex
tear solution. Mirejovsky’s ATS contains a range of different
proteins, lipids from different classification groups, and a non-
physiologic biochemical buffer. It was more complex than
many of the past solutions and the first to more accurately
mimic human tear fluid with individualized concentrations for
each component. Since the introduction of Mirejovsky’s ATS,
several  other  research  groups  have  begun  using  a  more
complex  ATS,  including  Prager  and  Quintana  [25,44],
Bontempo and Rapp [54,55], and Iwata et al. [56]. Prager and
Quintana’s [25,44] solution had the same protein portion as
the Mirejovsky ATS and the lipid portion was similar, but
instead  of  using  a  specialized  blend  of  salts,  Prager  and
Quintana used a Hank’s Balanced Salt solution as their saline
base. The Bontempo and Rapp [54,55] ATS incorporated five
tear film lipids, all incorporated in the same concentration,
three  tear  film  proteins,  all  incorporated  in  the  same
concentration,  and  a  0.9%  saline  base.  The  most  recent
solution of note is the one used by Iwata et al. [56] This
solution used a mixture of four lipids, three proteins and a
simplistic saline base [56].
It is common in in vitro ATS deposition models that the
ATS is a homogenous composition with the proteins, lipids,
and mucin mixed together throughout the solution. In other
words, the solution is not in the layered biophysical structure
as it is in the natural tear film. This is for several reasons; first,
in-vial  static  aqueous  incubations  are  not  conducive  to  a
lamellar structure, as the contact lens would not be exposed
to all of the tear film components as they are in human contact
lens wear. The blinking action, tear film mixing, tear film
thinning and the eventual tear film breaking that occurs in
Figure  6.  Phosphatidylcholine
deposition with and without lactoferrin
and immunoglobulin G for omafilcon A
and  balafilcon  A.  -LF/IgG=no
lactoferrin and immunoglobulin G in the
ATS.  +LF/IgG=lactoferrin  and
immunoglobulin G were present in the
ATS.
TABLE 7. CHOLESTEROL REPEATED MEASURES ANOVA RESULTS.
Variables SS DF MSq F p
Time 5255742 2 2627871 2774 <0.0001
±LF/IgG 851579 1 851579 1739 0.0006
Lens 21480765 1 21480765 24367 <0.0001
Time * ±LF/IgG 266177 2 133089 196 0.0001
Time * Lens 4865540 2 2432770 1506 <0.0001
±LF/IgG * Lens 634230 1 634230 794 0.0013
Time * ±LF/IgG * Lens 254090 2 127045 334 <0.0001
Error 1523 4 381    
               SS=sum of squares, DF=degrees of freedom, MSq=mean square, F=F statistic, p=probability.
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3400human contact lens wear exposes the lens to all layers and
components of the tear film. The second reason for using a
homogenous non-layered incubation solution is because this
model is simpler to execute and has similar deposited masses
of tear film components as ex vivo examined lenses [57,58].
Therefore, the biophysical arrangement of the ATS does not
impact deposition to the same extent as the interactions that
occur between the contact lens and tear film components.
Therefore, even though the ATS structure is not necessarily
identical to human tear film structure, it is still known to be a
good model for deposition and tear film interaction research.
Future models will incorporate a layered tear film analog and
incorporate air exposure, mimicking the inter-blink period.
With the modified ATS solution introduced in this paper,
we have tried to combine all of the necessary complexity by
incorporating a variety of lipids, proteins, mucin, salts and
also other prevalent tear film components such as physiologic
buffers, glucose and urea, all within a stable system specially
designed  for  in-vial  incubations.  All  of  these  previously
published  variations  on  an  ATS  are  indeed  a  great
improvement  over  the  more  simplistic  solutions  based,
primarily, on saline with a few added components. However,
none of the papers described has shown the stability of the
reported  solutions,  especially  in  terms  of  their  pH  and
osmolality during the various contact lens incubations. Work
in our laboratory during the development of this ATS clearly
demonstrated  the  importance  of  reduced  carbonates  and
increased phosphates in the complex saline solution, which
was used as the base solution, to maintain pH and osmolality
over time.
It is known that the pH and osmolality of a stable human
tear film is 6.6–7.8 [37] and 305 mmol/kg [59], respectively,
and that the surface tension of tears is 40–46 dynes/cm [60].
Therefore, we contend that the model ATS with the specific
complex salt solution introduced in this paper is a suitable
physical and chemical representation of the human tear film.
The  complex  salt  solution  introduced  in  this  paper  was
specially  designed  and  extensively  tested  to  confirm  its
stability. Many different combinations and concentrations of
salts and physiologic buffers were tested, however many of
the test solutions did not remain stable in pH or osmolality
over time. This was especially true for solutions with higher
concentrations of carbonates, as carbonates tend to react with
carbon dioxide in the air and therefore easily lead to a change
in pH, especially if vials are not tightly sealed. This process
was exacerbated when the ATS was incubated in plastic vials,
instead of glass. All plastic vials tested, including low-density
polyethylene, high-density polyethylene, super polyethylene,
and  Teflon-coated  plastic  vials  all  have  intrinsic  gas
permeability and therefore the pH and osmolality of the ATS
was  constantly  changing.  Therefore,  the  final  stable
physiologically relevant complex salt solution modified by
our laboratory contained only biologic buffers and a slightly
reduced  concentration  of  carbonates.  This  solution  was
specifically designed for closed in-vial incubations within
borosilicate glass vials with screw caps with PTFE liners that
are sealed with Parafilm®, so that ATS pH and osmolality
remained stable throughout the incubation periods.
In all of these papers on in vitro model systems, only one
of them has mentioned the lens parameter changes that occur
upon incubation. Pucker et al. [31] admit that due to the
incorporation of chloroform in their incubation solution, the
lens materials do indeed swell. Most of the other systems do
not have this chloroform addition and the extra solvents such
as hexane that may be present from the use of a lipid stock are
evaporated before lens incubation. None of the other papers
has reported measuring the diameter, center thickness or base
curve before incubation and following incubation in their ATS
to  know  if  the  composition  of  the  ATS  is  causing  lens
parameter changes beyond that which is considered allowable
by the FDA. Contact lenses and their cleaning solutions are
tightly regulated so that contact lens parameter changes do not
occur. According to the ISO tolerance guidelines [61], contact
lens materials are only allowed to change by ±0.20 mm in
diameter and base curve, and by approximately ±18 µm in
center  thickness,  depending  on  the  specific  lens  material,
during cleaning or contact lens wear. Swelling, stretching,
shrinking  and  curvature  changes  could  all  induce  power
TABLE 8. PHOSPHATIDYLCHOLINE REPEATED MEASURES ANOVA RESULTS.
Variables SS DF MSq F p
Time 476975 2 238488 737.92 <0.0001
±LF/IgG 889902 1 889902 1468.12 0.0007
Lens 3127668 1 3127668 2588.36 0.0004
Time * ±LF/IgG 30717 2 15358 21.80 0.0071
Time * Lens 221962 2 110981 424.64 <0.0001
±LF/IgG * Lens 212945 1 212945 440.59 0.0023
Time * ±LF/IgG * Lens 5516 2 2758 12.91 0.0180
Error 855 4 214    
               SS=sum of squares, DF=degrees of freedom, MSq=mean square, F=F statistic, p=probability.
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3401changes, fitting changes, and comfort issues for the contact
lens wearer. In an in vitro experiment, these changes can affect
contact  lens  deposition  and  interactions  with  tear  film
components so that the contact lenses no longer react naturally
to their surroundings.
In this experiment, the diameter, center thickness, and
base curve of all contact lens materials were measured directly
after removing them from the blister pack, following a soak
in CSS, and after two weeks of incubation in the artificial tear
solution  described.  The  diameter,  base  curve  and  center
thickness measurements all showed no clinically significant
changes following incubation in the ATS and no parameter
changes were found beyond what is allowed by 2006 ISO
18369–2  tolerance  guidelines  [61].  In  a  few  instances,
statistically significant changes in lens parameters were found
between  the  blister  pack  measurements  and  following
incubation in the ATS, however these changes were still well
within ISO tolerances.
As the final step in the development of this ATS, the ATS
was  tested  for  its  ability  to  deposit  lipid  onto  both  a
conventional  and  silicone  hydrogel  contact  lens  material.
Omafilcon A and balafilcon A lenses were chosen for the
experiment, as previous research has shown that conventional
hydrogels  tend  to  deposit  low  amounts  of  lipid,  whereas
silicone hydrogel lenses, especially balafilcon A, are known
to be more lipophilic and more likely to deposit lipid [28,56,
62]. Cholesterol and phosphatidylcholine were chosen for
examination  using  a  radiochemical  experiment.
Radiochemical  experiments  have  been  widely  used  in
biomaterials research [63-68] including contact lens research,
especially protein deposition research [18,24,25,29,30,69]. It
has been shown to be a very sensitive, repeatable and reliable
method of analysis and thus was chosen for this experiment.
Cholesterol was selected as a representative non-polar lipid as
it  has  been  widely  cited  to  be  one  of  the  most  prevalent
deposited lipids [57,62,70-72] and phosphatidylcholine was
chosen as a polar lipid species, due to its presence in the tear
film [11,73,74].
The results of the deposition experiment clearly showed
that lipid deposition, especially on balafilcon A lenses, tend
to continually deposit without a plateau effect throughout the
20 day incubation period, that the specific composition of the
ATS will have a large impact on the deposition pattern for
lipids,  and  that  cholesterol  tends  to  deposit  more  than
phosphatidylcholine.  Bontempo  and  Rapp  [54]  previously
examined the impact that ATS composition has on lipid and
protein deposition for conventional hydrogel lenses, but to
date nothing has been published on silicone hydrogel lens
materials.
This  research  supports  the  notion  that  the  specific
composition of an artificial tear solution will greatly impact
the mass of tear film components that deposit. By simply
removing  two  proteins  from  the  ATS  (lactoferrin  and
immunoglobulin G), lipid deposition significantly decreased.
Data has established that the incubation volume (not shown)
and  lipid  component  concentrations  [75]  also  affect  the
amount of lipid deposited. It is known that meibum, tear film,
and deposited lipid concentrations and compositions can vary
widely  between  individuals  and  that  diet,  medications,
systematic diseases, and work environment can influence this
deposition [6-9,76,77]. Therefore, it is very difficult to build
an in vitro model to fully mimic all of the relationships and
interactions that occur in human contact lens wear, so the first
step is to begin unraveling the factors that may influence
deposition.
When  the  deposited  mass  of  lipids  quantified  in  this
experiment is compared with other in vitro and ex vivo data,
it can be seen that differences do exist. In this experiment,
after 7 and 20 days of incubation in the ATS solution (+ LF/
IgG),  balafilcon  A  lenses  deposited  1.80±0.06  and
3.22±0.04 µg of cholesterol and 0.93±0.02 and 1.22±0.07µg
of phosphatidylcholine per lens, respectively. Omafilcon A
lenses  deposited  0.17±0.005  and  0.21±0.02  µg/lens  of
cholesterol after 7 and 20 days of incubation and similar
masses of phosphatidylcholine at the same time points. Much
of  the  other  in  vitro  lipid  work  completed  recently  has
quantified higher masses of cholesterol and phospholipids
(either  phosphatidylcholine  or  phosphatidylethanolamine)
depositing on balafilcon A and on conventional hydrogel lens
materials such as etafilcon A. In vitro work from Carney et al.
[28], Iwata et al. [56], and Pucker et al. [31], all cited higher
deposition values than the work presented here. However,
these other in vitro studies had one or more of these main
differences in their experimental design, which may account
for  increased  deposition  of  lipids:  the  use  of  single  lipid
incubation solutions, higher concentrations of lipids in the
ATS, altered incubation volumes, and replenishment of the
ATS with fresh solution during incubation [28,31,56]. All of
these factors may explain the higher deposition of cholesterol
and phosphatidylcholine.
When the cholesterol deposition results found in this in
vitro experiment are compared with recent ex vivo data it is
found that results from the balafilcon A material are quite
similar. Zhao et al. [57] quantified 4.1–8.2 µg/lens after 30
days of wear (depending on the cleaning solution used) and
Saville et al. [78] found 3.9 µg/lens after 30 nights of wear.
Saville [78] also examined phosphatidylcholine deposition
and quantified 0.019 µg/lens following 30 nights of wear,
which is lower than our quantified mass of 1.2 µg/lens on
balafilcon A. Many of the recent in vitro and ex vivo studies
were not completed with the same silicone hydrogel lens
materials,  did  not  include  conventional  hydrogel  lens
materials such as omafilcon A, and some of them examined
different lipids than those quantified in this experiment.
It is clear that in vitro models do not always directly
mimic  what  happens  in  vivo.  Many  times  the  masses
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3402deposited are lower or higher than what is reported in human
worn contact lenses. This may be due to the simplicity of the
models  being  used,  different  ATS  compositions  and
concentrations or an incomplete understanding of all of the
interactions and influences that are present. The only way that
in vitro models can be improved in their usefulness is to take
a more in-depth look at the relationships that are occurring
during human contact lens wear and then test and incorporate
them into the in vitro models. It may transpire that the success
of an in vitro model should not be measured according to the
absolute mass deposited during human contact wear, as these
values have large variations based on the populations tested,
but should be examined to see if the hierarchy of deposition
is consistent when comparing different lens materials and if
the trends of wear are predictive of human wear. In the end,
in vitro models must become more physiologically relevant
so that their use can be validated and provide a basis for
research and development of new and existing products.
As a first step in developing an in vitro model, the ATS
developed in our laboratory has been shown to remain stable
throughout  incubation  periods  up  to  four  weeks,  the  lens
parameters show no significant changes following a two week
incubation, and deposited lipids are in line with recent ex vivo
data.  The  ATS  solution  introduced  in  this  paper  has  the
flexibility to be tailored to the individual needs of the specific
in vitro experiment and can be used to mimic human worn
lens interactions and depositions.
Conclusion—This paper has introduced a novel complex
artificial  tear  solution  specially  designed  for  in-vial
incubations.  This  solution  maintains  its  own  solution
parameters and the parameters of the incubating contact lenses
constant. This solution characterization is the first step in
developing a new in vitro model for contact lens deposition
and tear film interactions.
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